

Appl. No. 09/694,519  
Atty. Docket No. 8311  
Amtd. Dated 2003-08-25  
Reply to Office Action of 03-24-2003  
Customer No. 27752

#### AMENDMENTS TO THE SPECIFICATION

Please amend the specification as follows:

Please replace the paragraph beginning at page 9, lines 1-11 with the following amended paragraph:

C 1

FIG. 3A and 3B demonstrate the anti-atrophy effects of VPAC<sub>1</sub> and VPAC<sub>2</sub> receptor selective agonists (administered subcutaneously, 2X daily) in the mouse glucocorticoid (dexamethasone)-induced atrophy model. FIG 3A shows the anti-atrophy effects of VPAC<sub>1</sub> and VPAC<sub>2</sub> receptor selective agonists in glucocorticoid-induced atrophied tibialis anterior muscle. FIG 3B shows the anti-atrophy effects of VPAC<sub>1</sub> and VPAC<sub>2</sub> receptor selective agonists in glucocorticoid-induced atrophied medial gastrocnemius muscle. Legend for the X-axis: [[A]] 1: Saline + Dexamethasone (1.2 mg/kg/day included in the drinking water), [[B]] 2: PACAP-38 (0.1 mg/kg) + Dexamethasone + T, [[C]] 3: PACAP-38 (0.3 mg/kg) + Dexamethasone + T, [[D]] 4: VPAC<sub>1</sub>R agonist (0.1 mg/kg) + Dexamethasone + T, [[E]] 5: VPAC<sub>1</sub>R agonist (0.3 mg/kg) + Dexamethasone + T, [[F]] 6: VPAC<sub>2</sub>R agonist (0.1 mg/kg) + Dexamethasone + T, [[G]] 7: VPAC<sub>2</sub>R agonist (0.3 mg/kg) + Dexamethasone + T.